Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunotherapeutics of multiple sclerosis.

L Durelli1

  • 1Istituto di Clinica delle Malattie del Sistema Nervoso Università di Torino, Italy.

Acta Neurologica
|October 1, 1991
PubMed
Summary

Immunosuppressive therapies offer targeted or broad immune system inhibition. While specific protocols are used, their efficacy lacks evidence, and side effects are a concern, especially with long-term use.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group--Italian Neurological Society.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2011
Same author

Neutralizing antibodies in multiple sclerosis patients treated with 375 micrograms interferon-beta-1b.

Expert opinion on biological therapy·2009
Same author

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.

The Cochrane database of systematic reviews·2008
Same author

MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosis.

Journal of neurology, neurosurgery, and psychiatry·2007
Same author

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab.

Multiple sclerosis (Houndmills, Basingstoke, England)·2006
Same author

Comparison of immunomodulatory treatments for multiple sclerosis.

European journal of neurology·2005

Area of Science:

  • Immunology
  • Pharmacology
  • Autoimmune Diseases

Background:

  • Immunosuppressive therapy can act specifically or broadly on the immune system.
  • Current low-dose protocols using corticosteroids or azathioprine lack evidence of efficacy.
  • Significant and serious side effects are associated with existing immunosuppressive treatments.

Purpose of the Study:

  • To review the mechanisms and efficacy of immunosuppressive therapies.
  • To evaluate the side effect profiles of various immunosuppressive agents.
  • To explore future directions in immunosuppressive treatment for autoimmune diseases.

Main Methods:

  • Review of existing literature on immunosuppressive therapy.
  • Analysis of clinical trial data for specific agents like cyclosporin-A and interferons.
  • Discussion of novel experimental approaches such as monoclonal antibodies and T cell vaccination.

Main Results:

  • High-dose immunosuppression may be better tolerated short-term and affect the central nervous system.
  • ACTH and methylprednisolone are recommended for short-term relapse management.
  • Alpha and beta-interferons show promise with a notable absence of significant side effects in ongoing trials.

Conclusions:

  • Specific immunosuppressive treatments are theoretically promising for future autoimmune disease therapy.
  • Ongoing research into agents like cyclosporin-A and copolymer 1 is crucial for understanding side effects.
  • Interferons represent a potentially safer therapeutic option, warranting further investigation.

Related Experiment Videos